研究级Atezolizumab生物类似药，内毒素0.05 EU/mg
研究级Atezolizumab生物类似药，内毒素0.05 EU/mg（Research grade Atezolizumab Biosimilar, Endotoxin 0.05 EU/mg）。研究级Atezolizumab生物类似药蛋白（research grade Atezolizumab biosimilar protein）仅用于研究用途(RUO)。我们也提供重组人IgG1同型对照抗体（Recombinant human IgG1 isotype control antibody）。Atezolizumab结合并阻断小鼠PD-L1，而不是durvalumab。
- 产品参数
- 文献
- More Offers
| 货号 | C024P.05 |
|---|---|
| 产品名称 | 研究级Atezolizumab生物类似药，内毒素0.05 EU/mg |
| 英文名 | Research grade Atezolizumab Biosimilar, Endotoxin 0.05 EU/mg |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | 悉得（Syd Labs） |
| 别称 | 程序性死亡配体1,PD-L1，分化簇274,CD274, B7同源物1,B7- h1 |
| 概述 | 研究级Atezolizumab生物类似药蛋白（research grade Atezolizumab biosimilar protein）仅用于研究用途(RUO)。我们也提供重组人IgG1同型对照抗体（Recombinant human IgG1 isotype control antibody）。Atezolizumab结合并阻断小鼠PD-L1，而不是durvalumab。 |
| 同种型 | 人 IgG1 kappa |
| 来源 | 抗人programmed cell death ligand 1 (PD-L1) 单克隆抗体atezolizumab生物类似药是使用atezolizumab生物类似药 CHO 稳定细胞系生产的。 |
| 特异性 | 体内实验级atezolizumab生物类似药（in vivo grade atezolizumab biosimilar specifically）与人PDL1蛋白特异性结合。 |
| 应用 | ELISA，中和，功能分析，如生物分析PK和ADA分析，以及研究受atezolizumab影响的生物途径的分析。 |
| 抗体形式 | 0.2 uM过滤溶液，pH 6.0，不含稳定剂或防腐剂。 |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质。C024P.05 内毒素≤0.05 EU/mg，提供特级研究级Atezolizumab生物类似药，内毒素0.05 EU/mg（Research grade Atezolizumab Biosimilar, Endotoxin 0.05 EU/mg，内毒素≤0.05 EU/mg)。 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 研究级Atezolizumab生物类似药，内毒素0.05 EU/mg（Research grade Atezolizumab Biosimilar, Endotoxin 0.05 EU/mg）用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 如果保存在2 至 8°C，自收到之日起可保存3个月。如果保存在-20 至 -70°C，自收到之日起可保存 12个月。 |
| 注意事项 | 研究级Atezolizumab生物类似药蛋白（research grade Atezolizumab biosimilar protein）仅用于研究用途(RUO)。我们也提供重组人IgG1同型对照抗体（Recombinant human IgG1 isotype control antibody）。Atezolizumab结合并阻断小鼠PD-L1，而不是durvalumab。 |
| 线下下单 | 武汉多找找科技有限公司 电话: 18162581039 微信: duozhaozhao2024 Email: message@sydlabs.com或联系我们 |
描述
C024P.05: 研究级Atezolizumab生物类似药，内毒素0.05 EU/mg（Research grade Atezolizumab Biosimilar, Endotoxin 0.05 EU/mg）
背景知识
What is Atezolizumab biosimilar research grade? Atezolizumab is a humanized monoclonal antibody directed against the human protein ligand PD-L1, with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab is an Fc-engineered, humanized, monoclonal antibody (IgG1κ isotype). Atezolizumab biosimilar uses the same protein sequences as the therapeutic antibody atezolizumab. Atezolizumab lacks the N-glycosylation site in its Fc region by changing an aspartic acid into alanine at amino acid position 298 (amino acid position 297 according to EU nomenclature, N297A) in the heavy chain leading to minimized binding to FcγRs.
PD-L1 (B7-H1 or CD274, programmed cell death ligand 1) and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed death 1). PD-L1 is an immune checkpoint molecule expressed on both tumor cells and certain immune cells. The binding of PD-L1 to its receptors PD-1 or B7.1 on activated T cells causes an inhibitory signal to suppress their production in the lymph nodes, thereby preventing immune responses to events such as pregnancy or autoimmune disease. This pathway is also utilized by cancer cells to evade the immune system through evasion of anti-tumor T-cell response. Furthermore, over-expression of PD-L1 and PD-1 has been linked to increased tumor aggressiveness and poorer prognosis. Atezolizumab binds directly and selectively to PD-L1 and blocks interaction with both PD-1 and B7.1 receptors, thus reinvigorates and enhances the body’s adaptive anti-cancer activity. Disrupting the PD-L1/B7.1 interaction may also enhance T-cell priming, which could result in increased duration of response and survival.
Syd Labs还提供以下研究级抗PD-L1 / PD-1抗体生物类似药蛋白（research grade anti-PD-L1 / PD-1 antibody biosimilar proteins）:
Atezolizumab生物类似药，研究级，抗人PD-L1单克隆抗体（Atezolizumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody）
Avelumab生物类似药，研究级，抗人PD-L1单克隆抗体（Avelumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody）
Camrelizumab生物类似药，研究级，抗人PD-1单克隆抗体（Camrelizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody）
Cemiplimab生物类似药，研究级，抗人PD-1单克隆抗体（Cemiplimab biosimilar, research grade, anti-human PD-1 monoclonal antibody）
Durvalumab生物类似药，研究级，抗人PD-L1单克隆抗体（Durvalumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody）
Nivolumab生物类似药，研究级，抗人PD-1单克隆抗体（Nivolumab biosimilar, research grade, anti-human PD-1 monoclonal antibody）
Pembrolizumab生物类似药，研究级，抗人PD-1单克隆抗体（Pembrolizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody）
Spartalizumab单抗生物类似药，研究级，抗人PD-1单克隆抗体（Spartalizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody）
PD-1是T细胞调节因子CD28/CTLA-4家族的一员。Syd Labs还提供以下研究级抗CTLA-4抗体生物类似药（research grade anti-CTLA-4 antibody biosimilars）:
Ipilimumab生物类似药，研究级，抗人CTLA-4单克隆抗体（Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody）
Tremelimumab生物类似药，研究级，抗人CTLA-4单克隆抗体（Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody）
Syd Labs提供以下抗小鼠PD-L1 / PD-1抗体（anti-mouse PD-L1 / PD-1 antibodies）:
体内实验级重组抗小鼠PD1单克隆抗体（克隆号29F.1A12.1）（In vivo grade recombinant anti-mouse PD1 monoclonal antibodies （Clone 29F.1A12.1））
体内实验级重组抗小鼠PD-1单克隆抗体（克隆号RMP1-14.1）（In vivo grade recombinant anti-mouse PD-1 monoclonal antibodies （Clone RMP1-14.1））
体内实验级重组抗小鼠PD-L1单克隆抗体（克隆号10F.9G2.1）（In vivo grade recombinant anti-mouse PD-L1 monoclonal antibodies （Clone 10F.9G2.1））
请记住我们的产品信息: 研究级Atezolizumab生物类似药，内毒素0.05 EU/mg: C024P.05 Syd Labs （Research grade Atezolizumab Biosimilar, Endotoxin 0.05 EU/mg）